Geron Co. (NASDAQ:GERN) has received a consensus rating of “Hold” from the six research firms that are presently covering the firm, Marketbeat.com reports. Four analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. The average 1-year target price among analysts that have issued ratings on the stock in the last year is $3.75.
Several equities research analysts have issued reports on GERN shares. Zacks Investment Research lowered shares of Geron from a “buy” rating to a “hold” rating in a research report on Tuesday, January 2nd. BidaskClub upgraded shares of Geron from a “strong sell” rating to a “sell” rating in a research report on Thursday, January 11th. Stifel Nicolaus reiterated a “hold” rating and set a $2.50 target price on shares of Geron in a research report on Friday, November 3rd. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Geron in a research report on Friday, November 3rd.
Shares of Geron (NASDAQ GERN) opened at $2.25 on Friday. Geron has a 1 year low of $1.74 and a 1 year high of $3.15. The stock has a market cap of $358.27, a P/E ratio of -12.50 and a beta of 2.81.
ILLEGAL ACTIVITY NOTICE: This piece of content was originally reported by Community Financial News and is the property of of Community Financial News. If you are reading this piece of content on another domain, it was stolen and republished in violation of international trademark and copyright laws. The original version of this piece of content can be accessed at https://www.com-unik.info/2018/02/10/geron-co-gern-receives-average-rating-of-hold-from-brokerages.html.
Geron Corporation (Geron) is a biopharmaceutical company, which supports the clinical stage development of a telomerase inhibitor, Imetelstat, in hematologic myeloid malignancies by Janssen Biotech, Inc (Janssen). The Company is engaged in the development of therapeutic products for oncology. Using its nucleic acid chemistry, Geron designed Imetelstat to be an oligonucleotide that binds with high affinity to the ribonucleic acid (RNA) template of telomerase, thereby directly inhibiting telomerase activity.
Receive News & Ratings for Geron Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Geron and related companies with MarketBeat.com's FREE daily email newsletter.